T H E N I H C A T A L Y S T | S E P T E M B E R O C T O B E R 2002 |
|
F R O M | T H E | D E P U T Y | D I R E C T O R | F O R | I N T R A M U R A L | R E S E A R C H |
WHAT
IS SPECIAL ABOUT THE INTRAMURAL
RESEARCH PROGRAM?
![]() |
Michael Gottesman |
.
. . SPECIAL
FEATURES OF THE IRP
. . . ENABLE OUR INTRAMURAL SCIENTISTS TO AVOID NONINNOVATIVE
SCIENCE AND PURSUE RISKIER PATHS THAT MAY OPEN ONTO MAJOR ADVANCES IN
OUR BASIC KNOWLEDGE AND CLINICAL ABILITIES
|
It is useful from time to time to re-evaluate the structure and function of the NIH intramural research programand the arrival of a new NIH director who asks for an overview of IRP contributions gives us the opportunity to do just that.
In a recent visit with the Scientific Directors, Dr. Zerhouni asked for examples of the IRPs past and continuing contributions to the overall NIH research effort. He was particularly interested in those that would be difficult or impossible to pursue using other funding mechanisms.
The resulting list was impressive and underscores the uniqueness of the research environment provided by NIH, the special features of the IRP that enable our intramural scientists to avoid noninnovative science and pursue riskier paths that may open onto major advances in our basic knowledge and clinical abilities.
Salient IRP characteristics include relatively long-term stable funding, which allows scientists to undertake research with a potentially high payoff but a long germination period; a critical mass of researchers who can interact collaboratively to assemble teams to attack complex problems; the ability to purchase major capital equipment and create facilities; short start-up time to address urgent problems in public health and to develop newly emerging scientific fields; and the premier clinical research facility in the country for conducting innovative research that takes basic science from bench to bedside.
Here are some examples of the research fostered by these unique features.
Long-term investment: Nobel prizewinning
contributions in establishing the genetic code, determining how neurons communicate,
and discovering the basis for transfer of information into cells by the action
of hormones, among others.
Teamwork: the development of vaccines against
hepatitis, childhood bacterial infections, and papillomaviruses associated with
cervical cancer, as well as other cancer vaccines; current work at the Vaccine
Research Center and NIAID to develop
a vaccine against HIV-AIDS and Ebola; and assembly of a critical mass of bioinformatics
expertise at the National Center for Biotechnology
Information, NLM, to archive and analyze DNA sequence information.
Resources: Powerful instruments including multi-Tesla
magnets and high-resolution microscopes to probe subcellular structures; MRI
equipment to visualize the functioning of the brain and heart; and an animal
imaging facility that is second-to-none in developing new technologies to yield
high-resolution images of normal and pathological tissue in animal model systems.
Short start-up: Response to HIV-AIDS epidemic
and biodefense needs; one of the first centers to adapt microarray technology
for diagnosis of cancer, to use positional cloning technology to isolate novel
disease genes, and to develop vectors that have facilitated the recombinant
DNA revolution.
Clinical research: Lithium to treat manic-depressive
illness; fluoride to prevent tooth decay; first artificial heart valve; multiple
chemotherapeutic agents to cure cancer; detection of hepatitis viruses to make
the blood supply safe; the first effective treatment of HIV-AIDS; development
of new approaches to organ and tissue transplantation, including transplantation
of pancreatic islet cells; the study of families with rare genetic diseases
to facilitate cloning of many different genes associated with human inherited
diseases such as Parkinsons disease and hereditary deafness syndromes;
and other population-based studies to determine the role of environmental and
genetic causes of human disease and to document biological changes associated
with normal development, aging, and drug and alcohol abuse.
To capitalize on the special features of the intramural program, especially the ability to bring state-of-the-art resources and teams of scientists to bear on difficult scientific problems over a long period of time, we have begun to design centers that allow even closer interaction of scientists with similar interests. The neuroscience center, emerging now in the southwest corner of the Bethesda campus, epitomizes this approach.
NIH intramural scientists have used the extraordinary opportunities inherent in the NIH way of doing research to great advantage. I encourage young scientists in training here to shy away from "me, too" science and avail themselves of the unique climate here for more creative work.
I am certain the readers of this essay can think of other unique features of the intramural program that have led to research with a major impact on modern biomedical research. As always, I welcome your thoughts and examples.
Michael
Gottesman
Deputy
Director for Intramural Research